CA2661293A1 - Combination treatment for metabolic disorders - Google Patents

Combination treatment for metabolic disorders Download PDF

Info

Publication number
CA2661293A1
CA2661293A1 CA002661293A CA2661293A CA2661293A1 CA 2661293 A1 CA2661293 A1 CA 2661293A1 CA 002661293 A CA002661293 A CA 002661293A CA 2661293 A CA2661293 A CA 2661293A CA 2661293 A1 CA2661293 A1 CA 2661293A1
Authority
CA
Canada
Prior art keywords
hydrogen
compound
methyl
diabetes
exendin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002661293A
Other languages
English (en)
French (fr)
Inventor
Stephen D. Wolpe
Ramachandran Arudchandran
Reid W. Von Borstel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wellstat Therapeutics Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2661293A1 publication Critical patent/CA2661293A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002661293A 2006-08-17 2007-08-16 Combination treatment for metabolic disorders Abandoned CA2661293A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US82267606P 2006-08-17 2006-08-17
US60/822,676 2006-08-17
PCT/US2007/076116 WO2008022267A2 (en) 2006-08-17 2007-08-16 Combination treatment for metabolic disorders

Publications (1)

Publication Number Publication Date
CA2661293A1 true CA2661293A1 (en) 2008-02-21

Family

ID=39083142

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002661293A Abandoned CA2661293A1 (en) 2006-08-17 2007-08-16 Combination treatment for metabolic disorders

Country Status (12)

Country Link
US (2) US20100227809A1 (enExample)
EP (1) EP2056673A4 (enExample)
JP (2) JP2010501010A (enExample)
KR (1) KR20090038908A (enExample)
CN (1) CN101505594A (enExample)
AU (1) AU2007285827A1 (enExample)
CA (1) CA2661293A1 (enExample)
IL (1) IL197001A0 (enExample)
MX (1) MX2009001763A (enExample)
NZ (1) NZ574664A (enExample)
WO (1) WO2008022267A2 (enExample)
ZA (1) ZA200900734B (enExample)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
CA2602854C (en) 2005-04-01 2013-05-14 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
US7772191B2 (en) 2005-05-10 2010-08-10 Boehringer Ingelheim International Gmbh Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
CA2639939A1 (en) * 2006-02-02 2007-08-16 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
WO2007128721A1 (de) 2006-05-04 2007-11-15 Boehringer Ingelheim Internationalgmbh Polymorphe
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
WO2009091732A1 (en) * 2008-01-15 2009-07-23 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
MX342806B (es) * 2008-03-13 2016-10-13 Wellstat Therapeutics Corp Compuestos y método para reducir el ácido úrico.
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
BRPI0916997A2 (pt) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh Inibidor de dpp-4 e seu uso
JP2012502081A (ja) 2008-09-10 2012-01-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糖尿病及び関連症状の治療のための組み合わせ治療
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
CN102256976A (zh) 2008-12-23 2011-11-23 贝林格尔.英格海姆国际有限公司 有机化合物的盐形式
TW201036975A (en) 2009-01-07 2010-10-16 Boehringer Ingelheim Int Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
TWI466672B (zh) * 2009-01-29 2015-01-01 Boehringer Ingelheim Int 小兒科病人糖尿病之治療
HUE050287T2 (hu) 2009-02-13 2020-11-30 Boehringer Ingelheim Int SGLT2-inhibitort, DPP-IV-inhibitort és adott esetben egy további antidiabetikus hatóanyagot tartalmazó gyógyászati készítmény és alkalmazásai
SG10201600204YA (en) 2009-02-13 2016-02-26 Boehringer Ingelheim Int SGLT-2 Inhibitor For Treating Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus, Impaired Glucose Tolerance Or Hyperglycemia
PT2486029E (pt) 2009-09-30 2015-10-14 Boehringer Ingelheim Int Processos para a preparação de derivados de benzil-benzeno substituídos com glucopiranosilo
US10610489B2 (en) 2009-10-02 2020-04-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof
EP2504002B1 (en) 2009-11-27 2019-10-09 Boehringer Ingelheim International GmbH Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
US9186392B2 (en) 2010-05-05 2015-11-17 Boehringer Ingelheim International Gmbh Combination therapy
BR112012032579B1 (pt) 2010-06-24 2021-05-11 Boehringer Ingelheim International Gmbh uso de linagliptina e composição farmacêutica compreendendo linagliptina e insulina basal de longa duração
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
AR085689A1 (es) 2011-03-07 2013-10-23 Boehringer Ingelheim Int Composiciones farmaceuticas de metformina, linagliptina y un inhibidor de sglt-2
PL2731947T3 (pl) 2011-07-15 2019-07-31 Boehringer Ingelheim International Gmbh Podstawiona dimeryczna pochodna chinazoliny, sposób jej wytwarzania i jej zastosowanie w kompozycjach farmaceutycznych do leczenia cukrzycy typu I i II
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US9192617B2 (en) 2012-03-20 2015-11-24 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
EP2849755A1 (en) 2012-05-14 2015-03-25 Boehringer Ingelheim International GmbH A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
EP4151218A1 (en) 2012-05-14 2023-03-22 Boehringer Ingelheim International GmbH Linagliptin, a xanthine derivative as dpp-4 inhibitor, for use in the treatment of sirs and/or sepsis
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
HK1213818A1 (zh) 2013-04-05 2016-07-15 勃林格殷格翰国际有限公司 依帕列净的治疗用途
HUE041709T2 (hu) 2013-04-05 2019-05-28 Boehringer Ingelheim Int Az empagliflozin terápiás alkalmazásai
CA2812519A1 (en) 2013-04-05 2014-10-05 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US11813275B2 (en) 2013-04-05 2023-11-14 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
RS63042B1 (sr) 2013-04-18 2022-04-29 Boehringer Ingelheim Int Farmaceutske kompozicije, metode lečenja i njihova upotreba
JP6615109B2 (ja) 2014-02-28 2019-12-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｄｐｐ−４阻害薬の医学的使用
CN109310697A (zh) 2016-06-10 2019-02-05 勃林格殷格翰国际有限公司 利格列汀和二甲双胍的组合
JP7625363B2 (ja) 2016-11-10 2025-02-03 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 医薬組成物、治療方法及びその使用
EP4681738A1 (en) 2023-03-14 2026-01-21 Suzhou Haiyi Biomedical Technology Co., Ltd 1,4-polyisoprene dispersion system, pharmaceutical active ingredient and use thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2277112C (en) * 1997-01-07 2008-08-26 Amylin Pharmaceuticals, Inc. Use of exendins and agonists thereof for the reduction of food intake
US6723530B1 (en) * 1997-02-05 2004-04-20 Amylin Pharmaceuticals, Inc. Polynucleotides encoding proexendin, and methods and uses thereof
US6902744B1 (en) * 1999-01-14 2005-06-07 Amylin Pharmaceuticals, Inc. Exendin agonist formulations and methods of administration thereof
US6924264B1 (en) * 1999-04-30 2005-08-02 Amylin Pharmaceuticals, Inc. Modified exendins and exendin agonists
US6506724B1 (en) * 1999-06-01 2003-01-14 Amylin Pharmaceuticals, Inc. Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus
ATE397938T1 (de) * 2000-05-19 2008-07-15 Amylin Pharmaceuticals Inc Behandlung des akuten koronaren syndroms mit glp- 1
MXPA03011558A (es) * 2001-06-12 2004-03-26 Wellstat Therapeutics Corp Compuestos para el tratamiento de desordenes metabolicos.
CA2502297C (en) * 2002-11-01 2011-12-13 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
EP1569682A2 (en) * 2002-12-03 2005-09-07 Novo Nordisk A/S Combination treatment using exendin-4 and thiazolidinediones
NZ542072A (en) * 2003-02-13 2007-11-30 Wellstat Therapeutics Corp Compounds for the treatment of metabolic disorders
WO2004091486A2 (en) * 2003-04-15 2004-10-28 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
WO2004098496A2 (en) * 2003-04-30 2004-11-18 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
JO2625B1 (en) * 2003-06-24 2011-11-01 ميرك شارب اند دوم كوربوريشن Phosphoric acid salts of dipeptidyl betidase inhibitor 4
US8273794B2 (en) * 2004-05-14 2012-09-25 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
CA2602854C (en) * 2005-04-01 2013-05-14 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
FR2887881B1 (fr) 2005-07-01 2009-10-09 Pierre Fabre Medicament Sa Inhibiteurs de proteines kinases
AU2007208127A1 (en) * 2006-01-25 2007-08-02 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
EP1976377A4 (en) * 2006-01-25 2010-06-23 Wellstat Therapeutics Corp COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS

Also Published As

Publication number Publication date
US20130137629A1 (en) 2013-05-30
WO2008022267A2 (en) 2008-02-21
KR20090038908A (ko) 2009-04-21
EP2056673A4 (en) 2010-06-16
AU2007285827A1 (en) 2008-02-21
EP2056673A2 (en) 2009-05-13
IL197001A0 (en) 2009-11-18
ZA200900734B (en) 2010-04-28
US20100227809A1 (en) 2010-09-09
NZ574664A (en) 2012-06-29
JP2010501010A (ja) 2010-01-14
WO2008022267A3 (en) 2008-07-03
JP2013091662A (ja) 2013-05-16
MX2009001763A (es) 2009-02-25
CN101505594A (zh) 2009-08-12

Similar Documents

Publication Publication Date Title
US20100227809A1 (en) Combination treatment for metabolic disorders
JP5072848B2 (ja) 低血糖イベントを低減するためのｄｐｐ−ｉｖ阻害剤の使用
Piya et al. Emerging treatment options for type 2 diabetes
Daskalopoulou et al. Effect on serum uric acid levels of drugs prescribed for indications other than treating hyperuricaemia
Tahrani et al. Saxagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus
Deacon et al. Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes
KR101438234B1 (ko) 의약의 병용 및 그 용도
Ahrén Vildagliptin: an inhibitor of dipeptidyl peptidase-4 with antidiabetic properties
Croom et al. Liraglutide: a review of its use in type 2 diabetes mellitus
JP2012092136A (ja) 哺乳動物の血糖値低下のためのジペプチジルペプチダーゼｉｖエフェクターの使用
PT1942898E (pt) Inibidores da dipeptidilpeptidase para o tratamento da diabetes
KR20120016051A (ko) 제약 조성물
JP2008517921A (ja) Ｄｐｐ−ｉｖ阻害剤、ｐｐａｒ抗糖尿病薬およびメトホルミンの組合わせ剤
US20130216625A1 (en) Treatment of insulin resistance or diseases associated with insulin resistance
MXPA05009789A (es) Combinacion de un antagonista del receptor de aldosterona y un agente antidiabetico.
JP2014001234A (ja) 糖尿病の合併症のための療法
TW200810743A (en) Combination of organic compounds
RU2358738C2 (ru) Лекарственные средства для лечения сахарного диабета
JPWO2006057152A1 (ja) タンパク質分解酵素阻害化合物からなる糖尿病治療剤
Salvatore et al. Progress in the oral treatment of type 2 diabetes: update on DPP-IV inhibitors
Wu et al. Dipeptidyl peptidase IV (DPP IV): a novel emerging target for the treatment of type 2 diabetes
US20140031347A1 (en) 1,2,4-oxadiazole derivatives as drugs modulating the glp-1 peptide receptor
KR101262123B1 (ko) 지질 대사 이상의 예방 또는 치료용 의약 조성물
Del Prato Dipeptidyl peptidase 4 inhibition and vildagliptin therapy for type 2 diabetes
MXPA06002127A (es) Terapia combinada para control glucemico.

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20140818